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See Article, pages 238–244Before the year 2000, serum ﬁbrosis markers were in an embry-
onic state of development [1–3]. Then along came an era of rapid
therapeutic advances in viral hepatitis, prompting the clinical
need for diagnosing liver ﬁbrosis simply, safely, and in the largest
number of candidates for therapy. As a consequence, the past 10
years have witnessed a ﬂurry of publications on newly identiﬁed
non-invasive ﬁbrosis markers. All of them have reported the area
under the receiver operating characteristic curves (AUROC) for
signiﬁcant ﬁbrosis, calculated sensitivity, speciﬁcity, and positive
and negative predictive values in cross-sectional studies, and as a
result, have claimed to be validated. Left with no choice in the
past, the clinician is now facing a bewildering situation each time
news about a new ﬁbrosis marker is published: what do we call
validation, howmuch validation is needed, and which test can we
trust in clinical practice?
The French National Authority for Health (Haute Autorité de
Santé) has issued a list of criteria for validation on which to base
the decision on whether to recommend each new non-invasive
method for assessing liver ﬁbrosis for use in clinical practice
(Table 1). Initial reports of most studies usually fulﬁll the ﬁrst
three criteria and report on an AUROC for differentiating
advanced vs. no/minimal ﬁbrosis ranging between 0.7 and 0.85.
Unsurprisingly, the higher the AUROC, the louder the claim of
‘‘validation”. The study by Cales et al., as reported in the current
issue of the Journal, brings these criteria a step further. The
authors present two new tests speciﬁcally developed for predict-
ing advanced ﬁbrosis in a population of HCV–HIV coinfected
patients. These tests are a simpliﬁcation of the original Fibrome-
ter [4], a proprietary non-ﬁbrosis marker which they share many
components with. The HICV test simply uses alpha 2 macroglob-
ulin, AST, and the prothrombin index. The second test, the
FibroMeter HICV uses, in addition, platelets, urea, and hyaluronic
acid, adjusted for age and sex. Using impeccable methodology in
both a derivation population (n = 183) and an independent mul-
ticentric validation population (n = 284), the authors demon-
strate that these tests perform better than other available tests,
including the original Fibrometer and the more popular Fibro-
Test. Why these slimmed down versions of the parent tests, cho-
sen empirically, perform better than the original ones is unclear.
Empiricism at its best, although already proven successful [4,5],
sometimes clashes with the legitimate claim for a scientiﬁc ratio-
nale. Inevitably, one is also left asking whether these second gen-Journal of Hepatology 20
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generation ones if they had been tested for the other common
liver diseases (HCV, HBV, alcoholic liver disease, or NAFLD) as
well. While waiting for these answers and going back to the ori-
ginal concern regarding the methodology of validation, the report
by Cales et al. is innovative, as the authors use a plethora of per-
formance indices, new in this ﬁeld. These include, but are not lim-
ited to: overall diagnostic performance, test performance proﬁle,
diagnostic accuracy, reliable diagnosis, reliable diagnosis inter-
vals, old and new, misclassiﬁcation rate, diagnostic cut-offs, over-
all test reproducibility, likelihood ratios, robustness, adjusted
AUROCS and the Obuchowski method [6]. This is more validation
than the average reader/clinician can comprehend. Moreover, by
showing higher scores for all these indices, the authors strive to
demonstrate that the new tests perform better than the previous
ones, as they provide a result closer to that of liver biopsy. This
raises two simple concerns. First, how legitimate is the race for
higher diagnostic indices vs. liver biopsy? Second, as the choice
of tests becomes larger and the validation that is presented for
each one increasingly sophisticated, should we constantly ask
for more validation or should we focus on the validation that will
make a difference for our clinical practice?
There is now enough data showing that the race for the high-
est AUROC or, by this account, any other diagnostic indices might
instead lead to a dead-end. Liver biopsy has signiﬁcant sampling
variability and even with a sample size of 25 mm, by all accounts
a good size for a biopsy, there is a 25% misclassiﬁcation rate
between adjacent METAVIR ﬁbrosis stages [7]. Trying to achieve
perfect concordance with a diagnostic procedure that has such
a high misclassiﬁcation rate is, to put it nicely, paradoxical. This
is intuitive reasoning, but in an elegant study [8] Mehta et al.
demonstrated that the variability of the results provided by liver
biopsy makes it impossible to achieve an AUROC close to 1, even
for a marker that measures the disease perfectly. For instance,
with conservative estimates of biopsy error, such as an 80% sen-
sitivity and speciﬁcity of biopsy and an advanced ﬁbrosis preva-
lence of 40%, a perfect test would have an expected AUROC vs.
liver biopsy of only 0.76. In the best case scenario (90% sensitivity
and speciﬁcity of liver biopsy) and for the same disease preva-
lence, the same perfect test will only reach an AUROC of 0.9
[8]. The optimistic interpretation of these simulations is that
some of the markers now available are already perfect. A more
realistic interpretation is that striving for the highest possible
AUROC vs. liver biopsy will amount to promoting a test that is10 vol. 53 j 222–224
Table 1
Minimal requirements for the validation of non-invasive ﬁbrosis markers
according to the French National Authority for Health (Haute Autorité de
Santé).*
Sufﬁciently large sample size; consecutive patients analyzed prospectively
Results reported separately for different etiologies of liver disease
Speciﬁcation of characteristics of liver biopsy (size, time interval between the
test, and biopsy)
Accessibility, reproducibility, including inter-laboratory variability, limits of
use and interpretation
At least one independent validation
* Adapted from: http://www.has-sante.fr/portail/jcms/c_476347/methodes-
devaluation-de-la-ﬁbrose-hepatique-au-cours-des-hepatopathies-chroniques,
accessed on April 10th 2010.
JOURNAL OF HEPATOLOGYas imperfect as liver biopsy itself. That does not make it simple to
compare two tests with different AUROCS, even in the same pop-
ulation: the one with the lowest AUROC might well be the more
accurate one!
There is yet another conceptual hurdle when trying to validate
a marker against liver biopsy, and this is our uncertainty about
what these markers are really measuring. Most studies report
proportional step-wise increases between test values and ﬁbrosis
stages. However, ﬁbrosis stages, especially in the METAVIR clas-
siﬁcation, are deﬁned primarily by architectural distortion rather
than by the amount of ﬁbrosis per se. Measurement of the area of
ﬁbrosis by micromorphometry (an accepted surrogate of the
amount of liver ﬁbrosis) has shown that the relationship with
the histological stages is all but linear: slight increases between
F0 and F2 and dramatic increases beyond F2 [7]. While it might
be reasonable to accept that direct or even indirect ﬁbrosis mark-
ers are correlated with the amount of ﬁbrosis, it does take a seri-
ous stretch of imagination to admit the rationale of their
correlation with the architectural changes which deﬁne the histo-
logical stages per se.
These two conceptual hurdles do not mean that serum ﬁbrosis
markers are not acceptable surrogates of liver ﬁbrosis and should
not be used for this purpose. But they should remind us that there
are serious limits in our understanding of their correlation with
the ﬁbrotic process in the liver and, most importantly, that there
is a clear limitation on how much validation we can achieve in
these type of cross-sectional studies vs. liver biopsy, given the
imperfect nature of the latter as a gold standard. Endless cross-
sectional validation of newer and older markers would only
achieve death by validation but not build the case for a more con-
vincing diagnostic alternative to liver biopsy. What type of vali-
dation is then critical, given the limits of liver biopsy and our
requirements for generalized use of these markers in clinical
practice?
First, analytical validation of these markers, especially serum-
based markers, is critical. As most of these markers simply calcu-
late a score based on locally obtained biological measurements,
the standardization of these measurements and their exportabil-
ity from one laboratory to another is critical. The variability of
some of the biological parameters such as aminotransferases is
of particular concern and needs to be minimized [9]. This is the
case for intra- and inter-laboratory variability, as well as preana-
lytical conditions of sampling and storage [10]. Even more impor-
tant is the assessment of intra-patient reproducibility. However
good the correlation with liver biopsy in an individual patient
may be, if short-term ﬂuctuations of the test are minimal, then
longer-term variations will most likely reﬂect true progressionJournal of Hepatology 201or regression of the disease. This will allow for conﬁdent long-
term patient monitoring. Unfortunately, with currently available
biomarkers of liver ﬁbrosis, an extensive analytical validation is
by far an exception rather than the rule.
A second major consideration is the exhaustive description of
precautions of use and limits of interpretation of any candidate
non-invasive marker. Just as we require the best understanding
of contraindications and precautions of use for pharmaceutical
agents, we should know when a test is at risk of providing unre-
liable results, either falsely positive or falsely negative. This
should start with an analysis of the reasons for discordant results
between the test and liver biopsy (or any better standard of com-
parison), acknowledging that when biopsy is used, biopsy itself
can be the reason for discordance [11]. An extensive analysis of
the prevalence of risk factors for false results should be con-
ducted in the general population and in that of patients with dif-
ferent liver diseases; whenever possible, measures to minimize
the impact of such a risk factor on the overall result should be
tested in order to provide the clinician with a robust result. The
bottom line is that clinicians should know when they can reason-
ably trust the test and when they should seek alternative diag-
nostic methods.
A third critical issue is the one circumventing the need for
liver biopsy in the validation process. Because of all the method-
ological issues related to the use of biopsy discussed above, we
clearly need alternative standards for validation. Ideally prognos-
tic analyses based on hard clinical end-points (liver-related
death, cirrhosis complications) would conﬁrm the clinical rele-
vance of these markers. Scarce studies in HCV [12], HBV [13],
alcoholic liver disease [14], and primary biliary cirrhosis [15]
are already available, but only for a few markers. Thresholds of
a speciﬁc marker, that place patients at risk for an adverse hepa-
tic outcome during mid or long-term follow-up, should be
deﬁned. This will help tremendously with the identiﬁcation of
individuals at risk of progression, with monitoring strategies
and with the optimization of indications for treatment. Another
important aspect is whether a non-invasive marker has the abil-
ity to capture changes in ﬁbrosis on therapy, independent of
improvement in inﬂammation or steatosis. Of note, markers that
include aminotransferases could be confounded by necrosis and/
or inﬂammation. Future trials should ideally incorporate sequen-
tial assessment of non-invasive markers in addition to end-of-
treatment biopsies [16], whenever applicable. Finally, I suggest
that the ultimate demonstration of the ability of a non-invasive
marker to replace liver biopsy for patient management, would
be the demonstration that basing the decision to treat on a
non-invasive marker rather than on liver biopsy would result in
the same proportion of eradicated patients. It is well known that
advanced ﬁbrosis reduces sustained viral response to the stan-
dard of care in chronic hepatitis C. A randomized trial where all
participants undergo both liver biopsy and a non-invasive marker
could be designed. The decision to treat should be based in one
arm on the results provided by liver biopsy, and in the other
arm on those provided by the surrogate marker. If, regardless of
the method chosen, the eradication rate is the same without
additional side effects, then it can be reasonably concluded that
non-invasive strategies could replace biopsy for uncomplicated,
ﬁrst-line therapeutic management. Despite all the studies pub-
lished on ﬁbrosis markers in the past decade, such a demonstra-
tion of the utility of any new marker for patient management is
not yet available.0 vol. 53 j 222–224 223
Editorial
The fourth and ﬁnal critical validation is, of course, the one
provided by truly independent studies in a variety of diseased
populations, not restricted to tertiary care centers. This type of
validation that conﬁrms diagnostic performances equivalent to
the ones originally described by the promoters of the tests, is
already available for both the FibroTest and the Fibrometer.
Finally, the article by Cales et al. raises challenging issues
related to the very design of a non-invasive marker. With the
notable exception of both FibroTest and Fibrometer, most serum
ﬁbrosis markers simply provide a binary information on the pres-
ence of advanced vs. no or mild ﬁbrosis. Given the sophistication
of the information provided by liver biopsy (5-point scale for
METAVIR, 7-point scale for Ishak ﬁbrosis staging systems) and
the way we have incorporated this in our clinical decision mak-
ing, this binary information appears to be an incongruous over-
simpliﬁcation. If a marker is to truly replace liver biopsy, it
should not only provide a truly quantitative measure, useful for
follow-up, but also a numerical equivalent to the commonly used
histological stages. Ideally, the value should reﬂect liver ﬁbrosis
independent of inﬂammatory activity or steatosis. Moreover,
were such a test to become a useful marker in primary care med-
icine, akin to markers of cardiovascular risk for instance, it should
be simple to use and interpret. Therefore at odds with what is
suggested by Cales et al., we should have a single and universal
marker of liver ﬁbrosis instead of different markers for different
etiologies [4], or distinct algorithms for diagnosing different
stages of the disease process [17].
Our understanding of the concept of diagnostic validation of
non-invasive markers has grown increasingly complex owing to
the many studies on serum ﬁbrosis markers published through-
out the last decade. One of the main lessons learned is that
cross-sectional validation vs. liver biopsy, although important
initially, has intrinsic limitations that will persist no matter
how much validation is provided. It is time to move forward from
this initial assessment towards a more clinically relevant valida-
tion process, encompassing altogether analytical, longitudinal,
prognostic, therapeutic, and independent validation. For some
markers most of this is already available. Whenever this is the
case, the clinician should take the leap of faith towards using
these tests in his or her own clinical practice.Conﬂict of interest
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